Print

Paquinimod

Paquinimod reduces skin fibrosis in tight skin 1 mice, an experimental model of systemic sclerosis. Stenström M., Nyhlén HC., Törngren M., Liberg D., Sparre B., Tuvesson H., Eriksson H., Leanderson T. J Dermatol Sci. 2016 Jul;83(1):52-9.

An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis (SSc) Patients Treated With Paquinimod (ABR-215757). Hesselstrand R, Distler JH, Riemekasten G,Törngren M, Carlsson-Nyhlen H, Stenström M, Andersson F, Eriksson H, Sparre B, Tuvesson H, Distler O. Poster presented at Eular Annual European Congress of Rheumatology - Paris 11-14 June 2014.
View the complete poster here

Pharmacokinetics, Tolerability, and Preliminary Efficacy of Paquinimod (ABR-215757), a New Quinoline-3-Carboxamide Derivative. Bengtsson A, Sturfelt G, Lood C, Rönnblom L, van Vollenhoven R.F, Axelsson B, Sparre B, Tuvesson H, Wallén-Öhman M, Leanderson T. Arthritis & Rheumatism, Vol. 64 No. 5, May 2012, pp 1579-1588.

Myeloid-related protein 14 promotes inflammation and injury in meningitis. Wache C, Klein M, Ostergaard C, Angele B, Häcker H, Pfister HW, Pruenster M, Sperandio M, Leanderson T, Roth J, Vogl T, Koedel U. J Infect Dis. 2015 Jul 15;212(2):247-57.

Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis. Schelbergen RF, Geven EJ, van den Bosch MH, Eriksson H, Leanderson T, Vogl T, Roth J, van de Loo FA, Koenders MI, van der Kraan PM, van den Berg WB1, Blom AB, van Lent PL. Ann Rheum Dis. 2015 Dec;74(12):2254-8.

The quinoline-3-carboxamide paquinimod (ABR-215757) reduces leukocyte recruitment during sterile inflammation: leukocyte- and context-specific effects. Deronic A, Helmersson S, Leanderson T, Ivars F. Int Immunopharmacol. 2014 Feb;18(2):290-7.

Beneficial effects of quinoline-3-carboxamide (ABR-215757) on atherosclerotic plaque morphology in S100A12 transgenic ApoE null mice. Yan L, Björk P, Butuc R, Gawdzik J, Earley J, Kim G, Hofmann Bowman MA. Atherosclerosis. 2013 May;228(1):69-79.Amelioration of Experimental Autoimmune Encephalomyelitis by the Quinoline-3-Carboxamide Paquinimod (ABR-215757) Reduced Priming of Proinflammatory Effector CD4+ T Cells. Helmersson A, Sundstedt A, Deronic A, Leanderson T, Ivars F. The American Journal of Pathology, Vol. 182, No. 5, May 2013.

Specific effect of immunomodulatory quinoline-3-carboxamide ABR-215757 in GM-CSF stimulated bo marrow cell cultures: block of initiation of proliferation of Gr-1+ cells. Helmersson S, Stenström M, Leanderson T, Ivars F.  Int Immunopharmacol. 2011 Aug;11(8):1045-51.

Selective depletion of splenic CD4 dendritic cells in mice treated with immunomodulatory quinoline-3-carboxamide ABR-215757. Stenström M, Anderson P, Eroukhmanoff L, Leanderson T, Ivars F. Int Immunopharmacol. 2010 Aug;10 (8):837-42.

Identification of Human S100A9 as a Novel target for Treatment of Autoimmune Disease via Binding to Quinoline-3-Carboxamides. Björk P, Björk A, Vogl T, Stenström M, Liberg D, Olsson A, Roth J, Ivars F, Leanderson T. PLoS Biology April 2009, Vol 7, Issue 4:800-812. http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1000097.